Open and Recruiting
Clinical Trials

• 

  A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ZW251 in Patients with Advanced Solid Tumors

  https://clinicaltrials.gov/study/NCT07164313?term=ZW251&rank=1

  • Sponsor

    Zymeworks

  • Trial ID

    NCT07164313

  • Study Details

    A Study of ZW251 in Participants With Advanced Solid Tumors

  • Study Url

    https://clinicaltrials.gov/study/NCT07164313?term=ZW251&rank=1

  • Cancer Type

    Advanced solid tumors

  • Status

    Preparing

  Brief Summary

  A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors, Including Hepatocellular Carcinoma

• 

  A Phase 1a/b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C137, an Antibody-Drug Conjugate Targeting FGFR2b, in Patients With Advanced Solid Tumors

  Study Details | NCT06625593 | A First-in-Human Study of BG-C137, an Anti-FGFR2b Antibody Drug Conjugate, in Participants With Advanced Solid Tumors | ClinicalTrials.gov

  • Sponsor

    BeOne Medicines, formerly BeiGene

  • Trial ID

    NCT06625593

  • Study Details

    A First-in-Human Study of BG-C137, an Anti-FGFR2b Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

  • Study Url

    https://clinicaltrials.gov/study/NCT06625593?term=BG-C137&rank=1

  • Cancer Type

    Advanced solid tumors

  • Status

    Preparing

For more information on phase one cancer
clinical trials,get in contact our team

Contact